These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 17336978

  • 1. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome.
    Romualdi D, Giuliani M, Draisci G, Costantini B, Cristello F, Lanzone A, Guido M.
    Fertil Steril; 2007 Jul; 88(1):131-8. PubMed ID: 17336978
    [Abstract] [Full Text] [Related]

  • 2. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.
    Garmes HM, Tambascia MA, Zantut-Wittmann DE.
    Gynecol Endocrinol; 2005 Dec; 21(6):317-23. PubMed ID: 16390779
    [Abstract] [Full Text] [Related]

  • 3. ACTH stimulation test in lean polycystic ovary syndrome patients with insulin resistance.
    Uncu G, Ozyurek SE, Uncu Y.
    Fertil Steril; 2007 Sep; 88(3):670-4. PubMed ID: 17451692
    [Abstract] [Full Text] [Related]

  • 4. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
    Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo R.
    Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
    [Abstract] [Full Text] [Related]

  • 5. Impact of glycemic variations on the regulation of androgen metabolism in obese women with polycystic ovary syndrome.
    Ludwig AK, Goharian LG, Dietze T, Tauchert S, Rudolf S, Diedrich K, Schweiger U, Oltmanns KM.
    Fertil Steril; 2009 Jul; 92(1):271-6. PubMed ID: 18692843
    [Abstract] [Full Text] [Related]

  • 6. Administration of exogenous ghrelin in obese patients with polycystic ovary syndrome: effects on plasma levels of growth hormone, glucose, and insulin.
    Guido M, Romualdi D, De Marinis L, Porcelli T, Giuliani M, Costantini B, Lanzone A.
    Fertil Steril; 2007 Jul; 88(1):125-30. PubMed ID: 17276431
    [Abstract] [Full Text] [Related]

  • 7. Effect of metformin on the growth hormone response to growth hormone-releasing hormone in obese women with polycystic ovary syndrome.
    Guido M, Romualdi D, Giuliani M, Suriano R, Tienforti D, Costantini B, Lanzone A.
    Fertil Steril; 2005 Nov; 84(5):1470-6. PubMed ID: 16275246
    [Abstract] [Full Text] [Related]

  • 8. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis.
    Azziz R, Black V, Hines GA, Fox LM, Boots LR.
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2317-23. PubMed ID: 9661602
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome.
    De Leo V, Morgante G, Piomboni P, Musacchio MC, Petraglia F, Cianci A.
    Fertil Steril; 2007 Jul; 88(1):113-7. PubMed ID: 17418832
    [Abstract] [Full Text] [Related]

  • 10. [Androgen response in women with polycystic ovary syndrome and hyperinsulinemia during stimulation with corticotrophin and inhibition with dexamethasone].
    Espinosa de los Monteros A, Guerra de la Garza A, Barrón J, Parra A.
    Rev Invest Clin; 1996 Jul; 48(4):267-73. PubMed ID: 8966389
    [Abstract] [Full Text] [Related]

  • 11. Adrenal function under long-term raloxifene administration.
    Genazzani AR, Lombardi I, Borgioli G, di Bono I, Casarosa E, Gambacciani M, Palumbo M, Genazzani AD, Luisi M.
    Gynecol Endocrinol; 2003 Apr; 17(2):159-68. PubMed ID: 12737677
    [Abstract] [Full Text] [Related]

  • 12. [Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion].
    Wang A, Li M, Lu C.
    Zhonghua Fu Chan Ke Za Zhi; 1998 Dec; 33(12):731-4. PubMed ID: 10806662
    [Abstract] [Full Text] [Related]

  • 13. Increased secretion of amylin in women with polycystic ovary syndrome.
    James S, Moralez J, Nagamani M.
    Fertil Steril; 2010 Jun; 94(1):211-5. PubMed ID: 19338997
    [Abstract] [Full Text] [Related]

  • 14. Evidence of a disturbance of the hypothalamic-pituitary-adrenal axis in polycystic ovary syndrome: effect of naloxone.
    Lanzone A, Guido M, Ciampelli M, Fulghesu AM, Pavone V, Proto C, Caruso A, Mancuso S.
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):73-7. PubMed ID: 8796141
    [Abstract] [Full Text] [Related]

  • 15. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G.
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [Abstract] [Full Text] [Related]

  • 16. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
    Romualdi D, De Marinis L, Campagna G, Proto C, Lanzone A, Guido M.
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
    [Abstract] [Full Text] [Related]

  • 17. Failure of the homeostatic model assessment calculation score for detecting metabolic deterioration in young patients with polycystic ovary syndrome.
    Fulghesu AM, Angioni S, Portoghese E, Milano F, Batetta B, Paoletti AM, Melis GB.
    Fertil Steril; 2006 Aug; 86(2):398-404. PubMed ID: 16769061
    [Abstract] [Full Text] [Related]

  • 18. Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin releasing factor (CRF).
    De Leo V, la Marca A, Lanzetta D, Cariello PL, D'Antona D, Morgante G.
    Clin Endocrinol (Oxf); 1998 Jul; 49(1):85-9. PubMed ID: 9797851
    [Abstract] [Full Text] [Related]

  • 19. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni VM.
    Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
    [Abstract] [Full Text] [Related]

  • 20. Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome.
    Moran C, Renteria JL, Moran S, Herrera J, Gonzalez S, Bermudez JA.
    Fertil Steril; 2008 Dec; 90(6):2310-7. PubMed ID: 18163993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.